Search
for
Sort by
Research 30 of 1000+
- Cutaneous reactions to targeted therapies in children with CNS tumors: A cross‐sectional study
- Cutaneous Reactions to Chemotherapeutic Agents
- Chemotherapy and Cutaneous Drug Reactions
- Cutaneous adverse events to systemic antineoplastic therapies: a retrospective study in a public oncologic hospital
- Cutaneous toxicities of cancer therapy
- Advances in the Management of Cutaneous Toxicities of Targeted Therapies
- Safety of Tyrosine Kinase Inhibitors in Patients With Differentiated Thyroid Cancer: Real-World Use of Lenvatinib and Sorafenib in Korea
- Cutaneous adverse effects of BRAF inhibitors in metastatic malignant melanoma, a prospective study in 20 patients.
- Non-Rash Skin Toxicities Associated with Novel Targeted Therapies
- Chemotherapy-induced iatrogenic injury of skin: New drugs and new concepts
- The incidence and management of cutaneous adverse events of the epidermal growth factor receptor inhibitors
- Sorafenib combined with hepatectomy in patients with intermediate-stage and advanced hepatocellular carcinoma
- Prophylaxis and Management of Skin Toxicities
- Dermatologic adverse events associated with chemotherapy and targeted anticancer therapy
- Cutaneous Adverse Events of Targeted Anticancer Therapy: A Review of Common Clinical Manifestations and Management
- Skin toxicity induced by chemotherapy or molecular targeted therapy combined with immune checkpoint inhibitors in Asian patients: A literature review by the Japanese Pharmacist-led Oncodermatology Study Team
- Chemotherapy and the Skin: Understanding Dermatologic Side Effects
- Diagnosis and treatment of cutaneous adverse effects of targeted therapy, antibody–drug conjugates, and immunotherapy in cancer patients: a national consensus statement by the Spanish Society of Medical Oncology and the Spanish Academy of Dermatology and Venereology
- Cutaneous Adverse Events of Tyrosine Kinase Inhibitors in Endocrine Tumors: Clinical Features, Mechanisms, and Management Strategies
- Dermatologic Side Effects of Systemic Targeted Anticancer Therapy
- Skin toxicity of anti‐cancer therapy
- The risk of dermatological toxicities of combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma patients: a systematic review and meta-analysis
- Cutaneous Drug Eruptions Associated with the Use of New Oncological Drugs
- Cutaneous toxicities of new targeted cancer therapies: must know for diagnosis, management, and patient-proxy empowerment
- Comparative Outcomes of Cutaneous Vesicostomy Versus Cystoscopic Valve Ablation in the Initial Management of Posterior Urethral Valves
- Cutaneous reactions to chemotherapeutic drugs and targeted therapy for cancer
- 567 Acute generalized exanthematous pustulosis (AGEP) induced by plaquenil
- Sorafenib-induced Facial Acneiform Eruption
- Acne inversa-like lesions associated with the multi-kinase inhibitor sorafenib
- Supportive Oncodermatology: Addressing dermatologic adverse events associated with oncologic therapies